Citations

Showing 10 of 108104 citations.

Dysregulated Spliceosome Activity Involves Increased Intron Retention Plus Upregulation and Phosphorylation of SF3B1 in Chronic Lymphocytic Leukemia
Lengerke-Diaz, Paula A. , Forero-Forero, José Vicente , Moreno, Eider, Luján, Juliana Vélez, Amaya-Chanaga, Carlos Ivan, Vidal, Newton Medeiros, Choi, Michael Y. , Rassenti, Laura Z., Mariño‐Ramírez, Leonardo , Diaz, Paula A Lengerke , Kashyap, Manoj Kumar , Karathia, Hiren , Kumar, Deepak , Alvarez, Roberto Vera , Forero, Jose V , Moreno, Eider, Yu, Zhe , Achinko, Daniel , Ghia, Emanuela M. , Mount, Stephen M. , Hannenhalli, Sridhar , Kipps, Thomas J. , Castro, Januario E.

Mayo Clinic

No container title available | May 11, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1622375/v1 Get It

Abstract BackgroundAlternative splicing (AS) is a fundamental process in eukaryotes contributing to the diversity of mRNA isoforms with variable ratios of intron/exon. SF3B1 is a pivotal protein of the spliceosome machinery. Mutations in the SF3B1 gene have prognostic value in Chronic Lymphocytic Leukemia (CLL). Our previous studies have shown that SF3B1 inhibition with macrolides induces apoptosis specifically in CLL compared with normal cells. SF3B1 inhibition is associated with a widespread increase in intron retention (IR) on most transcripts, suggesting that IR can be used as a marker of spliceosome inhibition in CLL cells. However, it is unknown how the activity of SF3B1 contributes to the spliceosome activity and the poor clinical prognosis in CLL.MethodsTo better understand this process, we performed a comprehensive analysis to quantify the abundance of individual exonic and intronic mapped reads on annotated RNA-Seq transcripts derived from the B cells of 98 CLL patients and nine healthy volunteers (Normal B cells – NBC). We calculated ratios for intron and exon abundance for each transcript and use this as a measure of intron retention (IR) and a surrogate for alternative splicing (AS).ResultsWe found that 66% of CLL B-cells transcripts had significant IR elevation compared to NBC and that transcripts with high IR were associated with low expression levels and mRNA downregulation. The IR increase in CLL B-cells was independent of prognostic factors such as IgVH or SF3B1 mutations. Transcripts with the highest IR levels belonged to biological pathways associated with gene expression and RNA splicing. Also, we observed a >2-fold increase of active pSF3B1 in CLL B-cells compared to NBC. Additionally, when the CLL-B cells were treated with macrolides (pladienolide-B), a significant decrease in pSF3B1, but not total SF3B1 protein was observed. ConclusionsOur findings suggest that IR/ARS is increased in CLL and that this process is associated with SF3B1 phosphorylation and susceptibility to SF3B1 inhibitors. These data provide additional support to the relevance of AS in carcinogenesis and evidence of pSF3B1 participation in this process.
Five Strategies for Bias Estimation in Artificial Intelligence-based Hybrid Deep Learning for Acute Respiratory Distress Syndrome COVID-19 Lung Infected Patients using AP(ai)Bias 2.0: A Systematic Review
Suri, Jasjit S. , Agarwal, Sushant , Jena, Biswajit , Agarwal, Vikas , Saba, Luca , Višković, Klaudija , Naidu, Subbaram, Agarwal, Vikas , Suri, Jasjit S. , Agarwal, Sushant, Saxena, Sanjay , El‐Baz, Ayman , Kalra, Mannudeep K. , Fatemi, Mostafa

Mayo Clinic

IEEE Transactions on Instrumentation and Measurement | May 11, 2022 | Volume: No volume available | Issue: No issue available | Pages: 1-1

10.1109/tim.2022.3174270 Get It

Targeting HER2 mutant advanced biliary tract cancers with neratinib: results from the SUMMIT ‘basket’ trial
Harding, James J. , Shah, Ronak , Murphy, Jessica, Cleary, James M. , Shapiro, Geoffrey I. , Moreno, Víctor , Loi, Sherene , Spanggaard, Iben , Park, Haeseong , Stemmer, Salomon M. , DiPrimeo, Daniel, Savin, Casey , Selçuklu, S. Duygu , Berger, Michael , Moreno, Victor , Loi, Sherene , Shapiro, Geoffrey I , Harding, James J , Piha‐Paul, Sarina A. , Quinn, David I , Braña, Irene , Borad, Mitesh J. , Ford, James M. , Arnedos, Mónica , Fouchardière, Christelle de la , Fountzilas, Christos , Zhang, Jie , Eli, Lisa D. , Meric‐Bernstam, Funda , Jhaveri, Komal , Solit, David B. , Abou‐Alfa, Ghassan K.

Mayo Clinic

No container title available | May 11, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1576467/v1 Get It

Abstract HER2 mutations are infrequent genomic events in biliary tract cancers (BTCs). Neratinib, an irreversible, pan-HER, oral tyrosine kinase inhibitor, interferes with constitutive receptor kinase activation and has activity in HER2-mutant tumours. SUMMIT is an open-label, single-arm, multi-cohort, phase 2, ‘basket’ trial of neratinib in patients with solid tumours harbouring oncogenic HER2 somatic mutations (NCT01953926). The primary objective of the BTC cohort was objective response rate (ORR). Among 25 treatment-refractory patients (11 cholangiocarcinoma, 10 gallbladder, 4 ampullary cancers), the ORR was 16%. The most common HER2 mutations were S310F (n = 11; 48%) and V777L (n = 4; 17%). Outcomes appeared worse for ampullary tumours or those with co-occurring oncogenic TP53 and CDKN2A alterations. Loss of amplified HER2 S310F and acquisition of multiple previously undetected oncogenic co-mutations were identified at progression in one responder. Neratinib demonstrated anti-tumour activity in patients with refractory BTC harbouring HER2 mutations. Future studies of rational combinations are warranted.
Decreasing Delirium through Music (DDM) in Critically Ill, Mechanically Ventilated Older Adults in the Intensive Care Unit: A Two-Arm, Parallel-group, Randomized Clinical Trial
Seyffert, Sarah , Moiz, Salwa, Coghlan, M.A. , Balozian, Patil, Nasser, Jason , Rached, Emilio Abi, Naqvi, Kiran , Rawlings, Lori, Gao, Sujuan , Downs, H. Robert, Khan, Sikandar , Khan, Babar , Jamil, Yasser , Naqvi, Kiran, Perkins, Anthony J. , III, Hunter Downs, Heiderscheit, Annie , Chlan, Linda L.

Mayo Clinic

No container title available | May 11, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1033106/v1 Get It

Abstract Background: Delirium is a highly prevalent and morbid syndrome in mechanically ventilated intensive care unit (ICU) patients. Music is a promising non-pharmacological intervention with beneficial effects on anxiety and stress, while its effects on delirium duration and severity are not well understood.Methods/design: Our study is a two-arm, randomized parallel-group, clinical trial to evaluate the efficacy of music intervention compared to a silence-track attention control on delirium/coma duration in mechanically ventilated critically ill older adults. One-hundred-sixty mechanically ventilated adults 50 years of age or older will be randomized to one of two arms within 72 hours of ICU admission: (1) one-hour music listening sessions twice daily through noise-cancelling headphones, or (2) one-hour sessions of a silence track twice daily through noise-cancelling headphones. Our primary aim is to compare delirium/coma free days after randomization during the 7-day study intervention phase using the Confusion Assessment Method for the ICU (CAM ICU) and the Richmond Agitation Sedation Scale (RASS) for delirium and coma. Secondary outcomes include pain and anxiety evaluated twice daily during the intervention phase and throughout the duration of ICU stay using the Critical Care Pain Observation Tool (CPOT) and Visual Analogue Scale-Anxiety (VAS-A). Enrolled participants will be followed after hospital discharge to further measure cognition as well as screening for depression and anxiety using the following telephone-based instruments: Indiana University Telephone-Based Assessment of Neuropsychological Status (IU TBANS), Patient Health Questionnaire-9 (PHQ-9), and Generalized Anxiety Disorder-7 (GAD-7).Discussion: This randomized clinical trial will measure the efficacy of a music listening intervention for delirium and coma duration early in the intensive care unit among older adults.Trial Registration: https://clinicaltrials.gov/ct2/show/NCT04182334
Dopamine receptor signaling regulates fibrotic activation of retinal pigmented epithelial cells
Gao, Ashley Y. , Link, Patrick A. , Bakri, Sophie J. , Haak, Andrew J. , Link, Patrick A

Mayo Clinic

American Journal of Physiology-Cell Physiology | May 11, 2022 | Volume: 323 | Issue: 1 | Pages: C116-C124

10.1152/ajpcell.00468.2021 | PMID 35544697 Get It

Retinal pigmented epithelial (RPE) cells play an important role in retinal fibrotic diseases such as proliferative vitreoretinopathy (PVR). The purpose of this study was to elucidate the involvement of dopamine receptor signaling in regulating the fibrotic activation of RPE cells. Dopamine receptor expression, the effect of dopamine on fibrotic activity, and dopamine production were measured in the human RPE cell line ARPE-19. The fibrotic activation of RPE cells was evaluated in response to treatments with selective dopamine receptor agonists and antagonists by measuring gene expression, migration, proliferation, and fibronectin deposition. DRD2 and DRD5 are the dominant dopaminergic receptors expressed in ARPE-19 cells and TGF-β stimulation enhances the autocrine release of dopamine, which we show further exasperates fibrotic activation. Finally, treatment with D2 dopamine receptor antagonists or D5 dopamine receptor agonists inhibits profibrotic gene expression, migration, proliferation, and fibronectin deposition and thus may serve as effective mechanisms for treating retinal fibrosis including PVR.
Guidelines for Reasonable and Appropriate Care in the Emergency Department 2 (GRACE‐2): Low‐risk, recurrent abdominal pain in the emergency department
Broder, Joshua , Silva, Lucas Oliveira J. e , Bellolio, Fernanda , Freiermuth, Caroline E. , Griffey, Richard T. , Hooker, Edmond A. , Jang, Timothy , Meltzer, Andrew C. , Pepper, Joan D., Prakken, Steven, Upadhye, Suneel , Broder, Joshua S , Oliveira J E Silva, Lucas , Hooker, Edmond , Jang, Timothy B , Mills, Angela M , Repplinger, Michael D , Upadhye, Suneel , Carpenter, Christopher R , Bellolio, M Fernanda , Griffey, Richard T , Meltzer, Andrew C , Mills, Angela M. , Carpenter, Christopher R.

Mayo Clinic

Academic Emergency Medicine | May 11, 2022 | Volume: 29 | Issue: 5 | Pages: 526-560

10.1111/acem.14495 | PMID 35543712 Get It

AbstractThis second Guideline for Reasonable and Appropriate Care in the Emergency Department (GRACE‐2) from the Society for Academic Emergency Medicine is on the topic “low‐risk, recurrent abdominal pain in the emergency department.” The multidisciplinary guideline panel applied the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess the certainty of evidence and strength of recommendations regarding four priority questions for adult emergency department patients with low‐risk, recurrent, undifferentiated abdominal pain. The intended population includes adults with multiple similar presentations of abdominal signs and symptoms recurring over a period of months or years. The panel reached the following recommendations: (1) if a prior negative computed tomography of the abdomen and pelvis (CTAP) has been performed within 12 months, there is insufficient evidence to accurately identify populations in whom repeat CTAP imaging can be safely avoided or routinely recommended; (2) if CTAP with IV contrast is negative, we suggest against ultrasound unless there is concern for pelvic or biliary pathology; (3) we suggest that screening for depression and/or anxiety may be performed during the ED evaluation; and (4) we suggest an opioid‐minimizing strategy for pain control.EXECUTIVE SUMMARYThe GRACE‐2 writing group developed clinically relevant questions to address the care of adult patients with low‐risk, recurrent, previously undifferentiated abdominal pain in the emergency department (ED). Four patient‐intervention‐comparison‐outcome‐time (PICOT) questions were developed by consensus of the writing group, who performed a systematic review of the literature and then synthesized direct and indirect evidence to formulate recommendations, following GRADE methodology. The writing group found that despite the commonality and relevance of these questions in emergency care, the quantity and quality of evidence were very limited, and even fundamental definitions of the population and outcomes of interest are lacking. Future research opportunities include developing precise and clinically relevant definitions of low‐risk, recurrent, undifferentiated abdominal pain and determining the scope of the existing populations in terms of annual national ED visits for this complaint, costs of care, and patient and provider preferences.
Packing the donor heart: Is SherpaPak cold preservation technique safer compared to ice cold storage
Bitargil, Macit , Haddad, Osama , Pham, Si M. , Garg, Neha , Jacob, Samuel , Ahmed, Magdy M. El‐Sayed , Landolfo, Kevin , Patel, Parag C. , Goswami, Rohan , Leoni, Juan , Yip, Daniel , Sareyyüpoğlu, Başar , El-Sayed Ahmed, Magdy M , Goswami, Rohan M , Leoni, Juan Carlos , Yip, Daniel S , Patel, Parag C. , Pham, Si , Garg, Neha , Goswami, Rohan

Mayo Clinic

Clinical Transplantation | May 11, 2022 | Volume: 36 | Issue: 8 | Pages: No page available

10.1111/ctr.14707 | PMID 35543679 Get It

AbstractIntroductionThe present study aimed to compare the clinical outcomes of heart transplant patients whose donor hearts were preserved with the SherpaPak controlled cold organ system versus the conventional ice storage technique.MethodsAll patients undergoing heart transplantation at our center between January 2019 and April 2021 were divided into two groups according to the technique used during donor heart preservation and transport. The first group consisted of 34 SherpaPak controlled temperature preservation patients, and the second group consisted of 47 patients where the conventional three bags and ice technique was utilized during organ transportation. The two groups were compared based on demographics, operative details, and postoperative outcomes.ResultsThere were no significant differences between the groups regarding Vasoactive Inotropic Score (VIS), Primary Graft Dysfunction (PGD), and the need for a transient pacer. However, the VIS, PGD, and pacing trends were lower in the SherpaPak patients even though the total ischemic and cardiopulmonary bypass times were significantly longer. Furthermore, SherpaPak patients exhibited a shorter stay in the ICU with no severe PGD and mortality.ConclusionThe SherpaPak donor heart preservation provides safe outcomes in heart transplant patients. Further research is needed to utilize this method for longer durations of ischemic time and expand travel distances for organ transportation.
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022
Alwan, Laura, Bachiashvili, Kimo, Baird, John H. , Cool, Rita, Dinner, Shira, Gojo, Ivana , Hicks, Ashley, Kidwai, Wajih Zaheer, Kloth, Dwight D. , Kraut, Eric H., Mahajan, Anjlee , Miller, Ryan, Nachar, Victoria , Patel, Shiven B. , Perez, Lia, Poust, Adam, Riaz, Fauzia , Rosovsky, Rachel , Simon, Shayna, Vasu, Sumithira , Wadleigh, Martha , Westbrook, Kelly , Westervelt, Peter, Berardi, Ryan A., Pluchino, Lenora A. , Griffiths, Elizabeth A. , Roy, Vivek , Geyer, Mark Blaine , Glaspy, John A. , Kallam, Avyakta , Landsburg, Daniel J. , Lyman, Gary H , Patel, Seema V. , Rugo, Hope S. , Simon, Shayna

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 11, 2022 | Volume: 20 | Issue: 5 | Pages: 436-442

10.6004/jnccn.2022.0026 | PMID 35545171 Get It

The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA). Management and prevention of these sequelae are an integral part of supportive care for many patients undergoing cancer treatment. The purpose of these guidelines is to operationalize the evaluation, prevention, and treatment of FN, CIT, and CIA in adult patients with nonmyeloid malignancies and to enable the patient and clinician to assess management options for FN, CIT, and CIA in the context of an individual patient’s condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for Hematopoietic Growth Factors, with particular emphasis on the incorporation of a newly developed section on CIT.
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, David S. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , Chirieac, Lucian R. , D’Amico, Thomas A., DeCamp, Malcolm M., Dilling, Thomas J. , Dowell, Jonathan E. , Gettinger, Scott , Gubens, Matthew A. , Lackner, Rudy P., Maldonado, Fabien , Morgensztern, Daniel , Ng, Thomas, Otterson, Gregory A. , Pacheco, Jose M., Patel, Sandip Pravin , Riely, Gregory J. , Riess, Jonathan W. , Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yang, Stephen C. , Yau, Edwin , Gregory, Kristina M., Hughes, Miranda, Schild, Steven E. , Bharat, Ankit , Chang, Joe Y. , Grotz, Travis E. , Hegde, Aparna , Lanuti, Michael D. , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Massarelli, Erminia , Tanvetyanon, Tawee , Yanagawa, Jane

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 11, 2022 | Volume: 20 | Issue: 5 | Pages: 497-530

10.6004/jnccn.2022.0025 | PMID 35545176 Get It

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) provide recommended management for patients with NSCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. Patients with metastatic lung cancer who are eligible for targeted therapies or immunotherapies are now surviving longer. This selection from the NCCN Guidelines for NSCLC focuses on targeted therapies for patients with metastatic NSCLC and actionable mutations.
Perspectives on Use of the Cutaneous Direct Immunofluorescence Assay
Lehman, Julia S. , Bridges, Alina G. , Lehman, Julia S , Culton, Donna Aline

Mayo Clinic

JAMA Dermatology | May 11, 2022 | Volume: 158 | Issue: 6 | Pages: 704

10.1001/jamadermatol.2022.1399 | PMID 35544127 Get It